NCT01523977 - Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

January 31, 2017

Study Completion Date

November 30, 2018

Conditions

Acute Lymphoblastic Leukemia

Interventions

DRUG

Everolimus

Orally, daily days 1-32 per assigned dose level

DRUG

Prednisone

40 mg/m2/day orally 3 x daily days 4-32

DRUG

Vincristine

1.5 mg/m2 IV daily on days 4, 11, 18, and 25

DRUG

PEG-Asparaginase

2,500 U/m2 IV 1 x daily on days 5 and 18

DRUG

Doxorubicin

30 mg/m2 IV on days 4 and 5

DRUG

Dexrazoxane

300 mg/m2 IV on days 4 and 5

Trial Locations (8)

Columbia University Medical Center, New York

Children's Healthcare of Atlanta, Atlanta

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

Children's Hospital Colorado, Aurora

UCSF, San Francisco

Seattle Children's Hospital, Seattle

Boston Children's Hospital, Boston

Dana-Farber Cancer Institute, Boston